🚀 VC round data is live in beta, check it out!
Adaptive Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for Adaptive Biotech and similar public comparables like VCANBIO, Syngene, Generate Biomedicines, Oxford Nanopore Technologies and more.
Adaptive Biotech Overview
About Adaptive Biotech
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Founded
2009
HQ
Employees
619
Website
Sectors
Financials (LTM)
EV
$2B
Adaptive Biotech Financials
Adaptive Biotech reported last 12-month revenue of $279M and EBITDA of $9M.
In the same LTM period, Adaptive Biotech generated $205M in gross profit, $9M in EBITDA, and had net loss of ($64M).
Revenue (LTM)
Adaptive Biotech P&L
In the most recent fiscal year, Adaptive Biotech reported revenue of $277M and EBITDA of $13M.
Adaptive Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $279M | XXX | $277M | XXX | XXX | XXX |
| Gross Profit | $205M | XXX | $206M | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $9M | XXX | $13M | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 5% | XXX | XXX | XXX |
| EBIT Margin | (22%) | XXX | (21%) | XXX | XXX | XXX |
| Net Profit | ($64M) | XXX | ($59M) | XXX | XXX | XXX |
| Net Margin | (23%) | XXX | (21%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Adaptive Biotech Stock Performance
Adaptive Biotech has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Adaptive Biotech's stock price is $14.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $-0.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAdaptive Biotech Valuation Multiples
Adaptive Biotech trades at 7.5x EV/Revenue multiple, and 229.6x EV/EBITDA.
EV / Revenue (LTM)
Adaptive Biotech Financial Valuation Multiples
As of April 19, 2026, Adaptive Biotech has market cap of $2B and EV of $2B.
Equity research analysts estimate Adaptive Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Adaptive Biotech has a P/E ratio of (34.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 7.5x | XXX | 7.5x | XXX | XXX | XXX |
| EV/EBITDA | 229.6x | XXX | 165.9x | XXX | XXX | XXX |
| EV/EBIT | (34.0x) | XXX | (36.6x) | XXX | XXX | XXX |
| EV/Gross Profit | 10.2x | XXX | 10.1x | XXX | XXX | XXX |
| P/E | (34.8x) | XXX | (37.5x) | XXX | XXX | XXX |
| EV/FCF | (110.7x) | XXX | (104.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Adaptive Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Adaptive Biotech Margins & Growth Rates
Adaptive Biotech's revenue in the last 12 month grew by 8%.
Adaptive Biotech's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.4M for the same period.
Adaptive Biotech's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Adaptive Biotech's rule of X is 5% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Adaptive Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 3% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | (93%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 2% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 35% | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 26% | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 34% | XXX | 34% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 95% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Adaptive Biotech Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Adaptive Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| VCANBIO | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene | XXX | XXX | XXX | XXX | XXX | XXX |
| Generate Biomedicines | XXX | XXX | XXX | XXX | XXX | XXX |
| Oxford Nanopore Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Suzhou Sepax Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adaptive Biotech M&A Activity
Adaptive Biotech acquired XXX companies to date.
Last acquisition by Adaptive Biotech was on XXXXXXXX, XXXXX. Adaptive Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Adaptive Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAdaptive Biotech Investment Activity
Adaptive Biotech invested in XXX companies to date.
Adaptive Biotech made its latest investment on XXXXXXXX, XXXXX. Adaptive Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Adaptive Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Adaptive Biotech
| When was Adaptive Biotech founded? | Adaptive Biotech was founded in 2009. |
| Where is Adaptive Biotech headquartered? | Adaptive Biotech is headquartered in United States. |
| How many employees does Adaptive Biotech have? | As of today, Adaptive Biotech has over 619 employees. |
| Who is the CEO of Adaptive Biotech? | Adaptive Biotech's CEO is Chad M. Robins. |
| Is Adaptive Biotech publicly listed? | Yes, Adaptive Biotech is a public company listed on Nasdaq. |
| What is the stock symbol of Adaptive Biotech? | Adaptive Biotech trades under ADPT ticker. |
| When did Adaptive Biotech go public? | Adaptive Biotech went public in 2019. |
| Who are competitors of Adaptive Biotech? | Adaptive Biotech main competitors are VCANBIO, Syngene, Generate Biomedicines, Oxford Nanopore Technologies. |
| What is the current market cap of Adaptive Biotech? | Adaptive Biotech's current market cap is $2B. |
| What is the current revenue of Adaptive Biotech? | Adaptive Biotech's last 12 months revenue is $279M. |
| What is the current revenue growth of Adaptive Biotech? | Adaptive Biotech revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of Adaptive Biotech? | Current revenue multiple of Adaptive Biotech is 7.5x. |
| Is Adaptive Biotech profitable? | Yes, Adaptive Biotech is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Adaptive Biotech? | Adaptive Biotech's last 12 months EBITDA is $9M. |
| What is Adaptive Biotech's EBITDA margin? | Adaptive Biotech's last 12 months EBITDA margin is 3%. |
| What is the current EV/EBITDA multiple of Adaptive Biotech? | Current EBITDA multiple of Adaptive Biotech is 229.6x. |
| What is the current FCF of Adaptive Biotech? | Adaptive Biotech's last 12 months FCF is ($19M). |
| What is Adaptive Biotech's FCF margin? | Adaptive Biotech's last 12 months FCF margin is (7%). |
| What is the current EV/FCF multiple of Adaptive Biotech? | Current FCF multiple of Adaptive Biotech is (110.7x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.